[Featured Stock] PeopleBio Establishes Foothold for European Expansion

The stock price of PeopleBio surged to the upper price limit. The news of signing a supply contract with a European screening center appears to have influenced the stock price. By partnering with a company operating global branches, PeopleBio has secured a foothold to enter the European market. The possibility of achieving quarterly profitability next year has increased.

At 2:52 PM on the 29th, PeopleBio was trading at 5,420 KRW, up 29.82% from the previous day.

On the same day, an economic newspaper reported that PeopleBio signed a contract to supply its early Alzheimer's disease diagnosis product, "AlzOn," to SYNLAB, the largest contract testing organization in Europe, through its Hungarian partner company.

SYNLAB provides screening services not only in Europe but also in more than 30 countries worldwide.